NeoGenomics, Inc. (NASDAQ:NEO) Shares Purchased by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC increased its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 11.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,350,746 shares of the medical research company's stock after buying an additional 236,924 shares during the quarter. Segall Bryant & Hamill LLC owned about 1.83% of NeoGenomics worth $22,309,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in NEO. Sterling Capital Management LLC lifted its stake in shares of NeoGenomics by 788.7% in the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock valued at $61,000 after purchasing an additional 3,289 shares during the last quarter. CWM LLC increased its holdings in NeoGenomics by 42.6% during the 1st quarter. CWM LLC now owns 6,299 shares of the medical research company's stock worth $60,000 after purchasing an additional 1,883 shares during the period. Sherbrooke Park Advisers LLC purchased a new stake in NeoGenomics during the 4th quarter worth about $183,000. Cibc World Markets Corp purchased a new stake in NeoGenomics during the 4th quarter worth about $197,000. Finally, Summit Investment Advisors Inc. increased its holdings in NeoGenomics by 6.9% during the 4th quarter. Summit Investment Advisors Inc. now owns 13,339 shares of the medical research company's stock worth $220,000 after purchasing an additional 863 shares during the period. Hedge funds and other institutional investors own 98.50% of the company's stock.

Wall Street Analysts Forecast Growth

NEO has been the subject of several analyst reports. The Goldman Sachs Group lowered their price objective on NeoGenomics from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Wall Street Zen raised NeoGenomics from a "sell" rating to a "hold" rating in a research report on Tuesday, May 13th. Piper Sandler set a $12.00 price objective on NeoGenomics and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Leerink Partnrs cut NeoGenomics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 30th. Finally, Guggenheim initiated coverage on NeoGenomics in a research note on Thursday, May 15th. They set a "neutral" rating on the stock. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $13.83.

NeoGenomics Trading Down 7.1%

Shares of NASDAQ:NEO traded down $0.48 during midday trading on Friday, reaching $6.24. The company's stock had a trading volume of 1,881,924 shares, compared to its average volume of 1,315,620. The firm has a market cap of $803.09 million, a price-to-earnings ratio of -10.23 and a beta of 1.63. The company has a quick ratio of 1.95, a current ratio of 2.05 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc. has a 1 year low of $6.08 and a 1 year high of $19.12. The business has a 50 day moving average price of $7.39 and a 200 day moving average price of $10.04.

NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). NeoGenomics had a negative return on equity of 2.21% and a negative net margin of 11.54%. The company had revenue of $168.04 million for the quarter, compared to analyst estimates of $171.38 million. During the same quarter in the prior year, the firm earned ($0.02) EPS. The company's revenue for the quarter was up 7.6% compared to the same quarter last year. Research analysts forecast that NeoGenomics, Inc. will post -0.2 EPS for the current year.

Insider Activity at NeoGenomics

In related news, Director Lynn A. Tetrault bought 7,000 shares of the stock in a transaction dated Friday, May 9th. The stock was bought at an average cost of $8.14 per share, with a total value of $56,980.00. Following the completion of the acquisition, the director owned 7,000 shares of the company's stock, valued at $56,980. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David Brian Perez acquired 10,000 shares of the firm's stock in a transaction that occurred on Monday, May 5th. The stock was acquired at an average cost of $7.63 per share, with a total value of $76,300.00. Following the completion of the acquisition, the director directly owned 10,000 shares in the company, valued at approximately $76,300. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders purchased 70,600 shares of company stock valued at $550,438. 2.40% of the stock is owned by insiders.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.